|
WO2020251781A1
|
|
Pharmaceutical formulations of bi-specific diabodies and use of the same
|
|
WO2020210277A1
|
|
Dosing regimens of bispecific cd123 x cds diabodies in the treatment of hematologic malignancies
|
|
WO2020092404A1
|
|
Bispecific cd123 x cd3 diabodies for the treatment of hematologic malignancies
|
|
WO2020041404A1
|
|
Pd-l1-binding molecules and use of the same for the treatment of disease
|
|
AU2019222666A1
|
|
Variant CD3-binding domains and their use in combination therapies for the treatment of disease
|
|
EP3724231A1
|
|
Bispecific cd 16-binding molecules and their use in the treatment of disease
|
|
US2019092860A1
|
|
Covalent Diabodies and Uses Thereof
|
|
MX2019009967A
|
|
Bispecific binding molecules that are capable of binding cd137 and tumor antigens, and uses thereof.
|
|
CA3048211A1
|
|
Adam9-binding molecules, and methods of use thereof
|
|
US2021061911A1
|
|
Dosing Regiments of Bi-Specific CD123 x CD3 Diabodies in the Treatment of Hematologic Malignancies
|
|
EP3463464A1
|
|
Combination therapy
|
|
KR20190016079A
|
|
Methods of using CD32B x CD79B-binding molecules in the treatment of inflammatory diseases and disorders
|
|
TW201737941A
|
|
Novel B7-H3-binding molecules, antibody drug conjugates thereof and methods of use thereof
|
|
TW201730212A
|
|
ROR1-binding molecules, and methods of use thereof
|
|
AU2016370376A1
|
|
Bispecific molecules having immunoreactivity with PD-1 and CTLA-4, and methods of use thereof
|
|
TW201720458A
|
|
Bi-specific monovalent diabodies that are capable of binding CD19 and CD3, and uses thereof
|
|
WO2017062615A2
|
|
Combination therapy for the treatment of cancer
|
|
WO2017062619A2
|
|
Combination therapy for the treatment of cancer
|
|
AU2016222331A1
|
|
Covalent diabodies and uses thereof
|
|
KR20180038045A
|
|
A bispecific monovalent diabody capable of binding to B7-H3 and CD3, and its use
|
